Organisation › Details

Ganymed Pharmaceuticals AG

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects. Ganymed's lead program, IMAB362, is in advanced phase II testing for gastroesophageal cancer. IMAB362 binds to the tight junction protein Claudin-18.2 which is expressed in up to 80% gastroesophageal adenocarcinomas, 60% pancreatic tumors as well as in other various solid tumors. Ganymed is also developing IMAB027, a monoclonal antibody targeting GT512 which is absent in healthy adult organs, but is expressed in a wide range of solid cancers, including testicular, ovarian, uterine, and lung cancers. The company plans to initiate clinical studies with IMAB027 in the near future. Ganymed is a private company that was founded in 2001 as a spin-off from the Universities of Mainz and Zurich. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. Other investors include Future Capital AG, MIG Fonds, First Capital Partner GmbH, and private individuals. *

 

Period Start 2001-01-01 established
  Group Astellas (Group)
Products Industry BIOTECH
  Industry 2 claudiximab (iMAB362/GC182)
Persons Person Türeci, Özlem (Ganymed 200811 CEO + CSO)
  Person 2 St-Onge, Luc (Apceth Biopharma 201708 before Ganymed + Affectis CBO + DeveloGen)
     
Region Region Mainz
  Country Germany
  Street 12 Freiligrathstr.
  City 55131 Mainz
  Tel +49-6131-1440-100
    Address record changed: 2018-07-24
     
Basic data Employees C: 51 to 100 (2016-10-28)
     
    * Document for �About Section�: Ganymed Pharmaceuticals AG. (9/11/13). "Press Release: Ganymed Pharmaceuticals Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors". Mechelen.
     
   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Astellas (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top